Filing Flows

Filing Flows › Companies › Senti Biosciences Holdings › Cash flow

Senti Biosciences Holdings cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$14.2M in Q2 2026 · −$38.1M over twelve months

Operating cash flow−$14.2M
Free cash flow−$14.2M

Analysis

In Q2 2026, Senti Biosciences Holdings generated −$14.2M of operating cash flow. That is $980K less than in Q2 2025 (−$13.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$38.1M; the largest uses were operating cash flow ($38.1M); besides operations, cash came from other financing ($20.2M), shares issued ($530K); the cash balance fell by $17.2M.

Operating cash flow was −$14.2M against net income of −$12.8M. The largest differences: payables +$1.2M, stock-based pay +$1.0M, accrued liabilities −$948K.

Free cash flow

Senti Biosciences Holdings: free cash flow by quarterSenti Biosciences Holdings: free cash flow by quarter−$7.9MQ3 2024−$13.5MQ4 2024−$14.1MQ1 2025−$13.3MQ2 2025−$9.4MQ3 2025−$6.9MQ4 2025−$7.5MQ1 2026−$14.2MQ2 2026
Operating cash flow less capital spending.
Senti Biosciences Holdings: operating cash flow against capital spendingSenti Biosciences Holdings: operating cash flow against capital spendingOperating cash flowCapital spending−$7.9M$0Q3 2024−$13.5M$11KQ4 2024−$14.1M$0Q1 2025−$13.1M$196KQ2 2025−$9.4M$0Q3 2025−$6.9M$0Q4 2025−$7.5M$0Q1 2026−$14.2M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$14.2M, Capital spending $0.

Capital allocation, year by year

Senti Biosciences Holdings: where the cash came from (up) and went (down), by fiscal yearSenti Biosciences Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$34.6MFY2021: Shares issued $68.5MFY2021: Capital spending −$5.5M$68.5MFY2021FY2022: Operating cash flow −$34.9MFY2022: Net borrowing $5.2MFY2022: Shares issued $1.2MFY2022: Capital spending −$41.4M$6.4MFY2022FY2023: Operating cash flow −$52.4MFY2023: Net borrowing −$108KFY2023: Shares issued $512KFY2023: Asset sales $105KFY2023: Capital spending −$12.0M$617KFY2023FY2024: Operating cash flow −$41.4MFY2024: Shares issued $6.7MFY2024: Asset sales $60KFY2024: Capital spending −$26K$6.8MFY2024FY2025: Operating cash flow −$43.4MFY2025: Shares issued $3.0MFY2025: Asset sales $12KFY2025: Capital spending −$196K$3.1MFY2025
Over these 5 years operating cash flow totalled −$207M; the largest uses were operating cash flow ($207M) and capital spending ($59.2M). Cash-flow statements as filed.

Where the cash came from and went

Senti Biosciences Holdings: sources (+) and uses (−) of cash, Q2 2026Senti Biosciences Holdings: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$14.2MOther financing$9.7MCash drawn (+) / kept (−)$4.6M
Senti Biosciences Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Senti Biosciences Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$38.1MOther financing$20.2MCash drawn (+) / kept (−)$17.2MShares issued$530KAsset & business sales$114K

From profit to cash

Senti Biosciences Holdings: net income to operating cash flow, Q2 2026Senti Biosciences Holdings: net income to operating cash flow, Q2 2026Net income−$12.8MDepreciation & amortization$667KStock-based pay$1.0MPayables$1.2MAccrued liabilities−$948KDeferred revenue−$16KOperating cash flow−$14.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$14.2M——$4.6M−$14.2M
Q1 2026−$7.5M——$7.5M−$7.5M
Q4 2025−$6.9M—$530K−$4.2M−$6.9M
Q3 2025−$9.4M——$9.3M−$9.4M
Q2 2025−$13.1M−$196K$1.0M$12.2M−$13.3M
Q1 2025−$14.1M—$1.5M$14.5M−$14.1M
Q4 2024−$13.5M−$11K$4.3M−$37.8M−$13.5M
Q3 2024−$7.9M—$2.4M$5.4M−$7.9M

Senti Biosciences Holdings: income statement and cash flow

Senti Biosciences Holdings, Q2 2026: revenue $17K. The chart follows the revenue to costs, profit and cash.

Senti Biosciences Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.